Phys Clinical Cases · haematological
Chronic Myeloid Leukaemia with Comorbidity — Clinical Case
DCE long case for chronic myeloid leukaemia: a 58-year-old man with newly diagnosed chronic-phase CML and significant cardiovascular comorbidity (prior myocardial infarction and hypertension). Full assessment, SASPOP opening, structured problem list, integrated management plan (the TKI choice constrained by cardiovascular risk — imatinib preferred over nilotinib for its vascular safety and over dasatinib for its pleural and pulmonary risk), BCR-ABL1 monitoring milestones, the rising-transcript workup, treatment-free remission candidacy, and probing examiner questions.
13 min readVerification in progress
On this page
Study tools
Target exams
FRACP DCEMRCP PACES
Prompt
DCE long case for chronic myeloid leukaemia: a 58-year-old man with newly diagnosed chronic-phase CML and significant cardiovascular comorbidity (prior myocardial infarction and hypertension). Full assessment, SASPOP opening, structured problem list, integrated management plan (the TKI choice constrained by cardiovascular risk — imatinib preferred over nilotinib for its vascular safety and over dasatinib for its pleural and pulmonary risk), BCR-ABL1 monitoring milestones, the rising-transcript workup, treatment-free remission candidacy, and probing examiner questions.
Chronic Myeloid Leukaemia with Comorbidity — Clinical Case
References5ShowHide
- [1]O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med, 2003.PMID 12637609
- [2]Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med, 2006.PMID 17151364
- [3]Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med, 2010.PMID 20525995
- [4]Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias N Engl J Med, 2013.PMID 24180494
- [5]Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Lancet Oncol, 2010.PMID 20965785